127 related articles for article (PubMed ID: 685736)
41. Response to crystalline 1alpha-hydroxyvitamin D3 in vitamin D dependency.
Reade TM; Scriver CR; Glorieux FH; Nogrady B; Delvin E; Poirier R; Holick F; DeLuca HF
Pediatr Res; 1975 Jul; 9(7):593-9. PubMed ID: 1161348
[TBL] [Abstract][Full Text] [Related]
42. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
43. The effect of 1,25(OH)2 vitamin D3 supplementation in premature infants.
Chan GM; Tsang RC; Chen IW; DeLuca HF; Steichen JJ
J Pediatr; 1978 Jul; 93(1):91-6. PubMed ID: 650355
[No Abstract] [Full Text] [Related]
44. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
Peacock M; Gallagher JC; Nordin BE
Lancet; 1974 Mar; 1(7854):385-89. PubMed ID: 4131034
[No Abstract] [Full Text] [Related]
45. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3.
Shiraki M; Ito H; Orimo H
Bone Miner; 1993 Mar; 20(3):223-34. PubMed ID: 8490326
[TBL] [Abstract][Full Text] [Related]
46. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
[TBL] [Abstract][Full Text] [Related]
47. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
48. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
49. [Treatment of patients with postmenopausal osteoporosis and steroid-induced osteoporosis with the preparation Rocaltrol (1,25/OH/2 vitamin D3)].
Koev D; Todorova S; Diankov L; Khristova D; Tsachev K
Vutr Boles; 1988; 27(2):117-22. PubMed ID: 3414094
[TBL] [Abstract][Full Text] [Related]
50. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
51. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
52. Effects of chlorothiazide on 1,25-dihydroxyvitamin D3, parathyroid hormone, and intestinal calcium absorption in the rat.
Favus MJ; Coe FL; Kathpalia SC; Porat A; Sen PK; Sherwood LM
Am J Physiol; 1982 Jun; 242(6):G575-81. PubMed ID: 6896403
[TBL] [Abstract][Full Text] [Related]
53. Effective long-term treatment of pseudohypoparathyroidism with oral 1alpha-hydroxy- and 1,25-dihydroxy-cholecalciferol.
Werder EA; Kind HP; Egert F; Fischer JA; Prader A
J Pediatr; 1976 Aug; 89(2):266-8. PubMed ID: 940021
[No Abstract] [Full Text] [Related]
54. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
55. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
[TBL] [Abstract][Full Text] [Related]
56. Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia.
Long RG; Varghese Z; Meinhard EA; Skinner RK; Wills MR; Sherlock S
Br Med J; 1978 Jan; 1(6105):75-7. PubMed ID: 620204
[TBL] [Abstract][Full Text] [Related]
57. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.
Argilés A; Kerr PG; Canaud B; Flavier JL; Mion C
Kidney Int; 1993 Mar; 43(3):630-40. PubMed ID: 8455362
[TBL] [Abstract][Full Text] [Related]
58. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
59. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
[TBL] [Abstract][Full Text] [Related]
60. 1-Alpha-hydroxycholecalciferol-induced changes in the renal heandling of phosphate and the serum parathyroid hormone level.
Madsen S; Olgaard K; Ladefoged J
Acta Med Scand; 1976; 200(5):351-4. PubMed ID: 983805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
